Hematology Frontier

The International Society on Thrombosis and Haemostasis (ISTH) announced the winners of the 2024 Fundamental Research Career Development Awards at the conference. This award aims to recognize early-career researchers who have made outstanding achievements in basic research. By acknowledging and encouraging these young scientists' innovative ideas, ISTH hopes to support them on their path to independent research, thereby strengthening the field of basic research. Each awardee will receive a grant to support their research, training, and collaborative studies in their respective fields. This award program, meticulously planned by the ISTH Fundamental Research Working Group under the guidance of the Education Committee, is designed as a career development incentive for promising early-career researchers.

From June 22 to June 26, 2024, the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference was successfully held in Bangkok, Thailand. At this prestigious event, the research achievements of Dr. Litao Zhang's team from Wuhan Asia General Hospital shone brightly. Several studies on anticoagulation management were selected, showcasing their significant contributions and expertise in the field of thrombosis and hemostasis. "Oncology Frontier - Hematology Frontier" invited Dr. Litao Zhang to comprehensively interpret the research content of his team. Here, we have compiled and invite you to join us in sharing this academic breeze.

Since 2015, the Chinese Society of Clinical Oncology (CSCO) has been dedicated to presenting annual reports on the progress of clinical oncology in China, under the theme "International Standards, Chinese Characteristics, Learning and Innovation." At the recent "2024 Annual Progress in Chinese Clinical Oncology Conference (BOC) and Best of ASCO 2024 China," the latest "Annual Advances in Chinese Clinical Oncology 2023" report was officially released. At this conference, Dr. Zhitao Ying from the Cancer Institute & Hospital Chinese Academy of Medical Sciences presented a detailed report on the advancements in lymphoma research in China for 2023.

In the realm of immunotherapy for lymphoma, PD-1/PD-L1 antibody combination therapies have emerged as a prominent area of research due to their precise modulation of the immune response. These therapies hold immense potential for enhancing efficacy and ensuring safety, providing lymphoma patients with more treatment options and the possibility of improved quality of life and prognosis. At the recent "2024 Nanjing Lymphoma Forum," Dr.  Huiqiang Huang from the Sun Yat-sen University Cancer Center delivered an outstanding presentation titled "Advances in Immunotherapy for Lymphoma: Clinical Exploration of PD-1/PD-L1 Antibody Combination Therapies." Following the forum, "Oncology Frontier - Hematology Frontier" invited Dr.  Huang for an interview to share further insights on this topic.

From June 22 to June 26, 2024, the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference was successfully held in Bangkok, Thailand. At this year's conference, a study by Dr. Zhangyin Ming's team from the School of Basic Medicine, Tongji Hospital of Huazhong University of Science and Technology, explored "The Role of Platelets in Epithelial-Mesenchymal Transition (EMT) and Tumor Metastasis of Cancer Cells in Situ." "Oncology Frontier - Hematology Frontier" invited Dr. Zhangyin Ming to provide an in-depth analysis of the research content. Here is a detailed summary for our readers.

Patients undergoing hematopoietic stem cell transplantation and high-dose chemotherapy for hematological diseases have impaired immune function, making them highly susceptible to febrile neutropenia and colonization or infection with resistant bacteria. Prompt and accurate initiation of empirical therapy is crucial to improve patient outcomes. At the 2024 European Hematology Association (EHA) Annual Meeting, Dr. Sizhou Feng's team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, reported a study showing a high proportion of bloodstream infections caused by carbapenem-resistant Acinetobacter spp. (CRA) in hematology patients, with homology between bloodstream isolates and colonizing bacteria. This indicates the need to strengthen hospital infection control to reduce resistant bacterial colonization and to promptly initiate appropriate empirical antimicrobial therapy for suspected infections in patients colonized with resistant bacteria. "Oncology Frontier - Hematology Frontier" invited Dr. Sizhou Feng to introduce and interpret this research at the EHA meeting.

Acute promyelocytic leukemia (APL) is a highly aggressive blood disorder, and its treatment has always been a challenge in the field of hematology. Chinese scholars have contributed the arsenic trioxide (ATO) regimen for global APL patients. Since the APL0406 study reported in the New England Journal of Medicine in 2013, all-trans retinoic acid (ATRA) combined with ATO has replaced ATRA combined with chemotherapy as the standard treatment for patients with intermediate and low-risk APL. However, whether this regimen is suitable for high-risk APL patients is still lacking in randomized controlled trial reports. At the 29th Annual Congress of the European Hematology Association (EHA 2024) held from June 13 to 16, 2024, Professor Uwe Platzbecker from Leipzig University in Germany presented the key results of the APOLLO study in an oral report. The study showed that the combination of ATO and ATRA provides a new treatment strategy for high-risk APL patients, offering valuable insights into the current state of APL treatment and guiding future research directions and clinical practices. "Oncology Frontier-Hematology Frontier" specially invited Professor Platzbecker on-site to share the important findings and clinical significance of the APOLLO study.

The 29th European Hematology Association (EHA) Annual Congress was held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars worldwide to share and discuss innovative ideas and the latest scientific and clinical research achievements in hematology. At this year's EHA Congress, three studies from Professor Sanbin Wang's team at The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army were selected as posters (abstracts P544, 965, and 420), exploring treatment advancements in AML, RRMM, and r/r B-ALL, respectively. Oncology Frontier-Hematology Frontier invited Professor Sanbin Wang to share and interpret the content and significance of these studies.